BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24984546)

  • 1. Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis.
    Togami S; Hori S; Kamio M; Matsuo T; Yoshinaga M; Douchi T
    Eur J Gynaecol Oncol; 2014; 35(3):301-3. PubMed ID: 24984546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.
    Kawata Y; Nagasaka K; Matsumoto Y; Oda K; Tanikawa M; Sone K; Mori-Uchino M; Tsuruga T; Arimoto T; Osuga Y; Fujii T
    Int J Clin Oncol; 2019 Apr; 24(4):420-427. PubMed ID: 30474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives.
    ; Matsusaki K; Ohta K; Yoshizawa A; Gyoda Y
    Int J Clin Oncol; 2011 Aug; 16(4):395-400. PubMed ID: 21347629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A New Treatment Strategy-Novel Cell-Free and Concentrated Ascites Reinfusion System(KM-CART)for Massive Malignant Ascites].
    Matsusaki K
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2490-2497. PubMed ID: 28028255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study.
    Yamamoto K; Nagao S; Tsu T; Matsushima T; Ishido Y; Narita M; Suzuki K; Nakazawa H; Shibutani T; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    J Obstet Gynaecol Res; 2021 Apr; 47(4):1536-1543. PubMed ID: 33469981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Case of Effective Palliative Care with CART for Refractory Ascites Associated with Cancerous Peritonitis of Gastric Cancer].
    Kawada J; Nishino M; Hata T; Ogino T; Hoshino H; Okano M; Nagai K; Kim Y; Okuyama M; Tsujinaka T
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):700-702. PubMed ID: 29650840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
    Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
    Tsubokura M; Adegawa Y; Kojima M; Tanosaki R; Ohtake R; Kase Y; Iwashita N; Kasane M; Nakabayashi S; Takeuchi S; Kato K; Boku N; Kanemitsu Y; Okusaka T; Fujimoto H; Yonemori K; Ishiki H; Kawamura K; Satomi E; Matsushita H
    BMC Cancer; 2022 Mar; 22(1):268. PubMed ID: 35287609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy.
    Okahisa T; Sogabe M; Nakagawa T; Tanaka K; Tomonari T; Taniguchi T; Takahashi A; Kinouchi Y; Nishioka J; Igata N; Yanagawa H; Komatsu T; Ohnishi Y; Fukuhara M; Ishikawa M; Shibata H; Shinomiya H; Nakasono M; Kishi F; Komai K; Tatsuki Y; Murashima T; Deguchi Y; Aramaki H; Fukumitsu H; Takayama T
    Artif Organs; 2020 Aug; 44(8):856-872. PubMed ID: 32187379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
    Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.
    Yamada Y; Inui K; Hara Y; Fuji K; Sonoda K; Hashimoto K; Kamijo Y
    Sci Rep; 2019 Jul; 9(1):10195. PubMed ID: 31308465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical Performance and Clinical Effectiveness of Drop Type With Adjustable Concentrator-Cell Free and Concentrated Ascites Reinfusion Therapy.
    Yamada Y; Harada M; Yamaguchi A; Kobayashi Y; Chino T; Minowa T; Kosuge T; Tsukada W; Hashimoto K; Kamijo Y
    Artif Organs; 2017 Dec; 41(12):1135-1144. PubMed ID: 28589706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.
    Kozaki K; IInuma M; Takagi T; Fukuda T; Sanpei T; Terunuma Y; Yatabe Y; Akano K
    Ther Apher Dial; 2016 Aug; 20(4):376-82. PubMed ID: 27523078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of cell-free and concentrated ascites reinfusion therapy (CART) in gynecologic cancer patients with a large volume of ascites.
    Wang L; Okubo T; Shinsaka M; Kobayashi A; Ogasawara M; Sakaguchi R; Nagai T; Seki H
    J Obstet Gynaecol Res; 2015 Oct; 41(10):1614-20. PubMed ID: 26177394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy.
    Nagata Y; Kato K; Miyamoto T; Hirano H; Shoji H; Iwasa S; Honma Y; Takashima A; Hamaguchi T; Matsushita H; Nagashima K; Saruta M; Boku N
    Support Care Cancer; 2020 Dec; 28(12):5861-5869. PubMed ID: 32253601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.
    Maeda O; Ando T; Ishiguro K; Watanabe O; Miyahara R; Nakamura M; Funasaka K; Kazuhiro F; Ando Y; Goto H
    Mol Clin Oncol; 2014 Nov; 2(6):1103-1106. PubMed ID: 25279205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study.
    Ishitani K; Isoai A; Ito T; Sugiyama H; Arakawa A; Yamada Y; Onodera H; Kobayashi R; Torii N; Soneda N; Matsuno Y; Utsugisawa T; Kato M; Hanafusa N
    Int J Clin Oncol; 2021 Jun; 26(6):1130-1138. PubMed ID: 33761026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
    Kim Y; Ajiki T; Ueda Y; Yoshida Y; Takahashi T; Fukuyama H; Fukuyama T; Hori Y
    Anticancer Res; 2024 Feb; 44(2):613-619. PubMed ID: 38307557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.